Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Dysfunctional HDL as a therapeutic target for atherosclerosis prevention.

Ossoli A, Pavanello C, Giorgio E, Calabresi L, Gomaraschi M.

Curr Med Chem. 2018 Mar 15. doi: 10.2174/0929867325666180316115726. [Epub ahead of print]

PMID:
29546829
2.

High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation.

Ruscica M, Botta M, Ferri N, Giorgio E, Macchi C, Franceschini G, Magni P, Calabresi L, Gomaraschi M.

Sci Rep. 2018 Feb 2;8(1):2236. doi: 10.1038/s41598-018-19568-8.

3.

Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction.

Zimetti F, De Vuono S, Gomaraschi M, Adorni MP, Favari E, Ronda N, Ricci MA, Veglia F, Calabresi L, Lupattelli G.

J Lipid Res. 2017 Oct;58(10):2051-2060. doi: 10.1194/jlr.P076463. Epub 2017 Aug 22.

4.

Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency.

Gomaraschi M, Ossoli A, Castelnuovo S, Simonelli S, Pavanello C, Balzarotti G, Arca M, Di Costanzo A, Sampietro T, Vaudo G, Baldassarre D, Veglia F, Franceschini G, Calabresi L.

J Lipid Res. 2017 May;58(5):994-1001. doi: 10.1194/jlr.P072371. Epub 2017 Mar 28.

5.

Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients.

Kempen HJ, Gomaraschi M, Simonelli S, Calabresi L, Moerland M, Otvos J, Jeyarajah E, Kallend D, Wijngaard PLJ.

Atherosclerosis. 2016 Dec;255:17-24. doi: 10.1016/j.atherosclerosis.2016.10.042. Epub 2016 Oct 24.

6.

Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial.

Ruscica M, Pavanello C, Gandini S, Gomaraschi M, Vitali C, Macchi C, Morlotti B, Aiello G, Bosisio R, Calabresi L, Arnoldi A, Sirtori CR, Magni P.

Eur J Nutr. 2018 Mar;57(2):499-511. doi: 10.1007/s00394-016-1333-7. Epub 2016 Oct 18.

7.

Lomitapide affects HDL composition and function.

Yahya R, Favari E, Calabresi L, Verhoeven AJM, Zimetti F, Adorni MP, Gomaraschi M, Averna M, Cefalù AB, Bernini F, Sijbrands EJG, Mulder MT, Roeters van Lennep JE.

Atherosclerosis. 2016 Aug;251:15-18. doi: 10.1016/j.atherosclerosis.2016.05.005. Epub 2016 May 11.

PMID:
27232459
8.

An Essential Role for Liver ERα in Coupling Hepatic Metabolism to the Reproductive Cycle.

Della Torre S, Mitro N, Fontana R, Gomaraschi M, Favari E, Recordati C, Lolli F, Quagliarini F, Meda C, Ohlsson C, Crestani M, Uhlenhaut NH, Calabresi L, Maggi A.

Cell Rep. 2016 Apr 12;15(2):360-71. doi: 10.1016/j.celrep.2016.03.019. Epub 2016 Mar 31.

9.

Protective Effects of HDL Against Ischemia/Reperfusion Injury.

Gomaraschi M, Calabresi L, Franceschini G.

Front Pharmacol. 2016 Jan 25;7:2. doi: 10.3389/fphar.2016.00002. eCollection 2016. Review.

10.

Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes.

Ossoli A, Remaley AT, Vaisman B, Calabresi L, Gomaraschi M.

Biochem J. 2016 Jan 15;473(2):211-9. doi: 10.1042/BJ20151000. Epub 2015 Nov 10.

PMID:
26556891
11.

Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease.

Zimetti F, Favari E, Cagliero P, Adorni MP, Ronda N, Bonardi R, Gomaraschi M, Calabresi L, Bernini F, Guardamagna O.

Atherosclerosis. 2015 Oct;242(2):443-9. doi: 10.1016/j.atherosclerosis.2015.08.007. Epub 2015 Aug 10.

PMID:
26291497
12.

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.

Gomaraschi M, Ossoli A, Adorni MP, Damonte E, Niesor E, Veglia F, Franceschini G, Benghozi R, Calabresi L.

Vascul Pharmacol. 2015 Nov;74:80-86. doi: 10.1016/j.vph.2015.06.014. Epub 2015 Jun 30.

PMID:
26133666
13.

Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.

Gomaraschi M, Adorni MP, Banach M, Bernini F, Franceschini G, Calabresi L.

Handb Exp Pharmacol. 2015;224:593-615. doi: 10.1007/978-3-319-09665-0_19. Review.

14.

HDL and atherosclerosis: Insights from inherited HDL disorders.

Calabresi L, Gomaraschi M, Simonelli S, Bernini F, Franceschini G.

Biochim Biophys Acta. 2015 Jan;1851(1):13-8. doi: 10.1016/j.bbalip.2014.07.015. Epub 2014 Jul 25. Review.

PMID:
25068410
15.

eNOS activation by HDL is impaired in genetic CETP deficiency.

Gomaraschi M, Ossoli A, Pozzi S, Nilsson P, Cefalù AB, Averna M, Kuivenhoven JA, Hovingh GK, Veglia F, Franceschini G, Calabresi L.

PLoS One. 2014 May 15;9(5):e95925. doi: 10.1371/journal.pone.0095925. eCollection 2014.

16.

Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice.

Pedrelli M, Davoodpour P, Degirolamo C, Gomaraschi M, Graham M, Ossoli A, Larsson L, Calabresi L, Gustafsson JÅ, Steffensen KR, Eriksson M, Parini P.

PLoS One. 2014 Apr 2;9(4):e93552. doi: 10.1371/journal.pone.0093552. eCollection 2014.

17.

Genetic determinants of HDL metabolism.

Ossoli A, Gomaraschi M, Franceschini G, Calabresi L.

Curr Med Chem. 2014;21(25):2855-63. Review.

PMID:
24606513
18.

Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus.

Ruscica M, Gomaraschi M, Mombelli G, Macchi C, Bosisio R, Pazzucconi F, Pavanello C, Calabresi L, Arnoldi A, Sirtori CR, Magni P.

J Clin Lipidol. 2014 Jan-Feb;8(1):61-8. doi: 10.1016/j.jacl.2013.11.003. Epub 2013 Nov 11.

PMID:
24528686
19.

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.

Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R.

J Clin Lipidol. 2013 Sep-Oct;7(5):414-22. doi: 10.1016/j.jacl.2013.06.007. Epub 2013 Jun 27.

PMID:
24079282
20.

Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

Kempen HJ, Gomaraschi M, Bellibas SE, Plassmann S, Zerler B, Collins HL, Adelman SJ, Calabresi L, Wijngaard PL.

J Lipid Res. 2013 Sep;54(9):2341-53. doi: 10.1194/jlr.M033779. Epub 2013 Jul 4.

21.

Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome.

Gomaraschi M, Ossoli A, Favari E, Adorni MP, Sinagra G, Cattin L, Veglia F, Bernini F, Franceschini G, Calabresi L.

Cardiovasc Res. 2013 Oct 1;100(1):36-43. doi: 10.1093/cvr/cvt169. Epub 2013 Jun 28.

PMID:
23812298
22.

Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.

Gomaraschi M, Ossoli A, Vitali C, Pozzi S, Vitali Serdoz L, Pitzorno C, Sinagra G, Franceschini G, Calabresi L.

Biochem Pharmacol. 2013 Feb 15;85(4):525-30. doi: 10.1016/j.bcp.2012.11.023. Epub 2012 Dec 5.

PMID:
23219857
23.

Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia.

Conca P, Pileggi S, Simonelli S, Boer E, Boscutti G, Magnolo L, Tarugi P, Penco S, Franceschini G, Calabresi L, Gomaraschi M.

J Clin Lipidol. 2012 May-Jun;6(3):244-50. doi: 10.1016/j.jacl.2012.01.006. Epub 2012 Jan 28.

24.

Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease.

Calabresi L, Simonelli S, Gomaraschi M, Franceschini G.

Atherosclerosis. 2012 Jun;222(2):299-306. doi: 10.1016/j.atherosclerosis.2011.11.034. Epub 2011 Nov 28. Review.

PMID:
22189200
25.

Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals.

Sirtori CR, Triolo M, Bosisio R, Bondioli A, Calabresi L, De Vergori V, Gomaraschi M, Mombelli G, Pazzucconi F, Zacherl C, Arnoldi A.

Br J Nutr. 2012 Apr;107(8):1176-83. doi: 10.1017/S0007114511004120. Epub 2011 Oct 28.

PMID:
22032303
26.

Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk.

Calabresi L, Baldassarre D, Simonelli S, Gomaraschi M, Amato M, Castelnuovo S, Frigerio B, Ravani A, Sansaro D, Kauhanen J, Rauramaa R, de Faire U, Hamsten A, Smit AJ, Mannarino E, Humphries SE, Giral P, Veglia F, Sirtori CR, Franceschini G, Tremoli E.

J Lipid Res. 2011 Aug;52(8):1569-74. doi: 10.1194/jlr.P014977. Epub 2011 May 19.

27.

Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations.

Gomaraschi M, Obici L, Simonelli S, Gregorini G, Negrinelli A, Merlini G, Franceschini G, Calabresi L.

Clin Chim Acta. 2011 Jun 11;412(13-14):1262-5. doi: 10.1016/j.cca.2011.03.027. Epub 2011 Mar 31.

28.

The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice.

Zanotti I, Maugeais C, Pedrelli M, Gomaraschi M, Salgam P, Calabresi L, Bernini F, Kempen H.

Br J Pharmacol. 2011 Nov;164(6):1642-51. doi: 10.1111/j.1476-5381.2011.01376.x.

29.

Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo.

Zanotti I, Pedrelli M, Potì F, Stomeo G, Gomaraschi M, Calabresi L, Bernini F.

Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):74-80. doi: 10.1161/ATVBAHA.110.213892. Epub 2010 Oct 21.

PMID:
20966401
30.

High-density lipoprotein quantity or quality for cardiovascular prevention?

Calabresi L, Gomaraschi M, Franceschini G.

Curr Pharm Des. 2010 May;16(13):1494-503. Review.

PMID:
20196739
31.

Structure and function of the apoA-IV T347S and Q360H common variants.

Gomaraschi M, Putt WE, Pozzi S, Iametti S, Barbiroli A, Bonomi F, Favari E, Bernini F, Franceschini G, Talmud PJ, Calabresi L.

Biochem Biophys Res Commun. 2010 Feb 26;393(1):126-30. doi: 10.1016/j.bbrc.2010.01.099. Epub 2010 Feb 1.

PMID:
20117098
32.

Native LDL-induced oxidative stress in human proximal tubular cells: multiple players involved.

Piccoli C, Quarato G, D'Aprile A, Montemurno E, Scrima R, Ripoli M, Gomaraschi M, Cirillo P, Boffoli D, Calabresi L, Gesualdo L, Capitanio N.

J Cell Mol Med. 2011 Feb;15(2):375-95. doi: 10.1111/j.1582-4934.2009.00946.x.

33.

A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred.

Calabresi L, Nilsson P, Pinotti E, Gomaraschi M, Favari E, Adorni MP, Bernini F, Sirtori CR, Calandra S, Franceschini G, Tarugi P.

Atherosclerosis. 2009 Aug;205(2):506-11. doi: 10.1016/j.atherosclerosis.2009.01.006. Epub 2009 Jan 15.

PMID:
19200546
34.

Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia.

Cefalù AB, Noto D, Magnolo L, Pinotti E, Gomaraschi M, Martini S, Vigna GB, Calabresi L, Tarugi P, Averna MR.

Atherosclerosis. 2009 May;204(1):202-7. doi: 10.1016/j.atherosclerosis.2008.08.031. Epub 2008 Sep 4.

PMID:
18926541
35.

The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction.

Gomaraschi M, Sinagra G, Serdoz LV, Pitzorno C, Fonda M, Cattin L, Calabresi L, Franceschini G.

Atherosclerosis. 2009 Jan;202(1):304-11. doi: 10.1016/j.atherosclerosis.2008.04.004. Epub 2008 Apr 12.

PMID:
18486943
36.

Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.

Gomaraschi M, Calabresi L, Rossoni G, Iametti S, Franceschini G, Stonik JA, Remaley AT.

J Pharmacol Exp Ther. 2008 Feb;324(2):776-83. Epub 2007 Nov 27.

37.

Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant.

Gomaraschi M, Baldassarre D, Amato M, Eligini S, Conca P, Sirtori CR, Franceschini G, Calabresi L.

Circulation. 2007 Nov 6;116(19):2165-72. Epub 2007 Oct 22.

38.

Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients.

Eberini I, Gianazza E, Breghi L, Klugmann S, Calabresi L, Gomaraschi M, Mombelli G, Brusoni B, Wait R, Sirtori CR.

Ann Med. 2007;39(4):306-11.

PMID:
17558602
39.

A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux.

Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L.

J Biol Chem. 2007 Feb 23;282(8):5125-32. Epub 2006 Dec 12.

40.

Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection.

Bellosta S, Gomaraschi M, Canavesi M, Rossoni G, Monetti M, Franceschini G, Calabresi L.

FEBS Lett. 2006 Oct 30;580(25):5974-8. Epub 2006 Oct 12.

41.

Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury.

Calabresi L, Gomaraschi M, Rossoni G, Franceschini G.

Pharmacol Ther. 2006 Sep;111(3):836-54. Review.

PMID:
16960983
42.

High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease.

Gomaraschi M, Calabresi L, Franceschini G.

Expert Opin Ther Targets. 2006 Aug;10(4):561-72. Review.

PMID:
16848692
43.

High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli.

Gomaraschi M, Basilico N, Sisto F, Taramelli D, Eligini S, Colli S, Sirtori CR, Franceschini G, Calabresi L.

Biochim Biophys Acta. 2005 Sep 15;1736(2):136-43.

PMID:
16135414
44.

PPARs - First International Symposium. From basic science to clinical applications. 4-7 April 2001, Florence, Italy.

Calabresi L, Gomaraschi M.

IDrugs. 2001 Jul;4(7):750-3. No abstract available.

PMID:
15995925
45.

European Atherosclerosis Society--75th congress.

Gomaraschi M.

IDrugs. 2005 Jul;8(7):555-9.

PMID:
15973562
46.

Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury.

Rossoni G, Gomaraschi M, Berti F, Sirtori CR, Franceschini G, Calabresi L.

J Pharmacol Exp Ther. 2004 Jan;308(1):79-84. Epub 2003 Oct 17.

47.

Endothelial protection by high-density lipoproteins: from bench to bedside.

Calabresi L, Gomaraschi M, Franceschini G.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1724-31. Epub 2003 Sep 11. Review.

PMID:
12969988
48.
49.
50.

Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):656-61.

PMID:
11950706

Supplemental Content

Loading ...
Support Center